Impact of Adding Favipiravir to Hydroxychloroquine and Azithromycin Treatment on QTc Interval in COVID-19

Basit Öğe Kaydı
dc.contributor.authorÇerik, Idris Buğra
dc.contributor.authorÖztürk Çerik, Hatun
dc.contributor.authorDoğan, Ahmet
dc.contributor.authorDereli, Seçkin
dc.contributor.authorBektaş, Osman
dc.contributor.authorKaya, Yasemin
dc.date.accessioned2024-10-26T17:51:18Z
dc.date.available2024-10-26T17:51:18Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjective: The Coronavirus disease-2019 (COVID-19) pandemic has caused the death of many people worldwide. Treatment protocol had to be developed as soon as possible so drug combinations, whose reliability has not been fully disclosed, have started to be used. In this study, we aimed to evaluate the effect of azithromycin (AZT), hydroxychloroquine (HCQ), and favipiravir (FVR) combination on the corrected QT (QTc) interval. Material and Methods: Eighty-four consecutive COVID 19 patients were enrolled in the study. All patients received AZT and HCQ, however, FVR was added to the combination in 32 patients with severe pneumonia at the beginning. ECG characteristics of all patients before treatment and on the fifth day of treatment were compared. Results: There was no significant difference between the HCQ+AZT group (n=52) and HCQ+AZT+FVR groups (n=32) in terms of baseline clinical characteristics. QTc interval significantly prolonged on the fifth day of treatment in the HCQ+AZT group (413,75±30,13; 440,27±36,11 p<0.001) and in the HCQ+AZT+FVR group (426,65±32,83; 468,22±42,13 p<0.001). When both groups were compared in terms of ?QTc, a significant increase was observed in the HCQ+AZT+FVR group compared to the HCQ+AZT group (40(-14/175), 23(-28/213) respectively, p=0.042). In seven of the patients, QTc> 500 ms was detected after the treatment, four patients in the HCQ+AZT+FVR group and three patients in the HCQ+AZT group. Conclusion: We observed that FVR caused more prolongation in the QTc interval when used with the combination of HCQ+AZT. We recommend that patients who receive this treatment be monitored more closely for QTc. Copyright © 2021 by Türkiye Klinikleri.
dc.identifier.doi10.5336/cardiosci.2020-80082
dc.identifier.endpage21
dc.identifier.issn1306-7656
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85113179594
dc.identifier.scopusqualityQ4
dc.identifier.startpage15
dc.identifier.trdizinid491623
dc.identifier.urihttps://doi.org/10.5336/cardiosci.2020-80082
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/491623
dc.identifier.urihttps://hdl.handle.net/20.500.12418/26153
dc.identifier.volume33
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherOrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.
dc.relation.ispartofTurkiye Klinikleri Cardiovascular Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectazithromycin; favipiravir; hydroxychloroquine; aged; antiviral therapy; Article; clinical feature; coronavirus disease 2019; disease severity; drug effect; drug safety; electrocardiogram; electrocardiography; female; human; loading drug dose; major clinical study; male; pneumonia; QT prolongation; QTc interval; retrospective study
dc.titleImpact of Adding Favipiravir to Hydroxychloroquine and Azithromycin Treatment on QTc Interval in COVID-19
dc.title.alternativeHidroksiklorokin ve Azitromisin Tedavisine Favipiravirin Eklenmesinin COVID-19’da QTc Aralığı Üzerindeki Etkisi
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu